Search Results
Your search for ,are matches 22257 pages
Showing 301 - 350TP53 Mutation Acquisition Timing Influences Prognosis in MPNs, Study Finds
The timing of TP53 mutation acquisition carries important prognostic implications for patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes/MPN overlap disorders. Later emergence of the mutation is associated with significantly worse survival outcomes, according to a...
Machine Learning Model May Improve Accuracy of Liquid Biopsy Results
A machine learning model developed by researchers at the Johns Hopkins Kimmel Cancer Center filters out the biological noise in liquid biopsy samples, helping clinicians better match therapies to their patients’ tumors. These findings were published by Canzoniero et al in Clinical Cancer Research....
Long-Term Outcomes of Adjuvant Hypofractionated Radiotherapy for Breast Cancer
As reported in The Lancet Oncology by Brunt et al, long-term follow-up of the UK phase III FAST-Forward trial has shown that a 1-week adjuvant radiotherapy schedule was associated with good outcomes at 10 years in patients with breast cancer. Study Details In the multicenter, open-label,...
Urologic Surgeon Sworn in as AMA President
Willie Underwood III, MD, MSc, MPH, a urologic surgeon based in Buffalo, New York, was sworn on June 9 as the 181st President of the American Medical Association (AMA). Assuming the presidency at a pivotal moment for American health care, Dr. Underwood pledged during his inaugural address at AMA...
Perioperative Serplulimab in PD-L1–Positive Gastric Cancer
In a Chinese phase III study (ASTRUM-006) reported in The Lancet, Shen et al found that neoadjuvant serplulimab plus S-1/oxaliplatin (SOX) followed by adjuvant serplulimab improved event-free survival vs neoadjuvant and adjuvant SOX in patients with PD-L1–positive, resectable gastric or...
Can AI Provide an ‘Early Alert’ for Breast Cancer Before Diagnosis?
Three commercially available radiology artificial intelligence (AI) systems have shown the potential to flag early signs of breast cancer up to 6 years before a diagnosis, according to a Swedish study published by Hickman et al in Radiology. In a retrospective study, researchers tested three...
Rami Manochakian, MD, FASCO, on Updates on SCLC: No Longer Too Small to Ignore
Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, summarizes an educational session at ASCO that reviewed the state of the field of small cell lung cancer (SCLC) treatment. After decades of limited treatment progress, advances are being seen in immunotherapies, radiation therapy, bispecific...
Coming Out in the Exam Room
Preparing for a patient I was going to see in breast oncology clinic, I noticed she was single and that her partner was female. The information system at the hospital I was working in included a patient photograph along with the usual demographic and clinical information. The photograph had caught ...
I’ve Beaten the Odds for Stage IV Lung Cancer
I learned that I had advanced stage non-small cell lung cancer (NSCLC) soon after a physician in the emergency department handed me the results of a computed tomography (CT) scan, which showed that I had lesions on my L3 and L4 vertebrae. The report stated that these lesions “were highly concerning ...
‘I’d Like to Agree With You…But Then We Would Both Be Wrong’
I am pleased to respond to the Letter to the Editor from Davis and Wolinsky printed in this issue of The ASCO Post, disagreeing with my views about screening for prostate cancer.In brief, the key points of my commentary were as follows: PSA is a useful tool in the management of prostate cancer;...
Prostate Cancer Screening Controversies
We read with interest the recent commentary by Derek Raghavan, MD, PhD, FACP, FASCO, FRACP, on ‘Prostate Screening Saved My Life’ Is That Really True in Most Cases?’ (The ASCO Post, April 25, 2026).1 As patient advocates, we agree with Dr. Raghavan on one important point: simplistic claims such as...
Advancing Clinical Trials and Decision-Making With Synthetic Real-World Data
Synthetic real-world data generated by AI can model treatment patterns and clinical outcomes across large patient cohorts while accelerating clinical trials and drug development, according to Eddy Saad, MD, MSc, a Research Fellow in Medicine at Dana-Farber Cancer Institute. During a presentation...
How New York City—and the Nation—Got Its First Cancer Hospitals
Editor’s Note: On May 1, 2026, The New York Historical, an American history museum and library in New York City, published the following blog post by Leland Jasperse, PhD, in its From the Stacks collection. The story, “How New York City—and the Nation—Got Its First Cancer Hospitals,” chronicles the ...
2026 ASCO Breakthrough Meeting to Highlight New Advances in Liquid Biopsy, Metabolic Risks, and Tailored Therapies for Asian Populations
The ASCO Breakthrough meeting being held in Singapore this month will bring together global oncology professionals in Asia to discuss the latest cancer research advances across multiple disease sites that are shaping the future of patient care. New studies featured in the official Press Program...
ASCO Updates Policy Statement on 340B Drug Pricing Program
Early last month ASCO published an updated policy statement on the 340B Drug Pricing Program in JCO Oncology Practice.1 The update proposes a package of recommendations to expand practice eligibility, address potential abuses, and ensure the 340B program benefits the patients it was intended to...
Expanded Living Guidelines Program Ushers in a New Era for ASCO Guidelines
ASCO initiated its guideline program in 1993 and published the first guideline on colony stimulating factors in 1994.1 ASCO has evolved from publishing one or two guidelines annually to maintaining a robust library of over 118 guidelines with new guidelines added annually. Today, ASCO publishes...
Another Point of View: Reefer Madness!
The conclusions drawn from the study by Johnson et al1 appear overstated and should be interpreted with caution. In the study discussed in this issue of The ASCO Post, investigators compared breast and testicular cancer incidence trends in American states that had or had not legalized the use of...
‘The Science and Practice of Translation: Improving Cancer Outcomes Worldwide’
“Good morning, and welcome to the 62nd Annual Meeting of ASCO! ¡Buenos días, y bienvenidos a la sexagésima segunda reunión anual de ASCO! This is the world’s largest cancer research conference and the premier global platform for oncology innovation! But what brings us together today is not just...
Can Psychostimulants Treat Cancer-Related Fatigue?
A new meta-analysis provides updated evidence that methylphenidate-type psychostimulants—a class of medications that increase dopamine and norepinephrine availability in the brain—can provide meaningful relief for cancer-related fatigue. The study was published in the May 2026 issue of...
Daraxonrasib in KRAS-Mutant Pancreatic Cancer: A First Step in Shifting the Paradigm of Treatment
Wolpin and colleagues have demonstrated in the global randomized Phase III RASolute 302 trial that daraxonrasib, an oral RAS(ON) inhibitor, nearly doubles median overall survival in previously treated metastatic pancreatic ductal adenocarcinoma, producing a median overall survival of 13.2 months...
Review of Breast Cancer News and Studies
Among the high-quality abstract presentations at ASCO and the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. The ASCO Post asked its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his selection and thoughts on some...
Weighing the Evidence Supporting Aspirin vs GLP-1 RAs in Colorectal Cancer Prevention
A study by Jones et al offers a provocative contribution to the landscape of colorectal cancerprevention by directly comparing two pharmacologic strategies with markedly different historical roles in prevention (see sidebar on page 47).1 Aspirin has long served as the benchmark for primary...
A Burning Question: Can Wildfire Smoke Drive Cancer Risk?
Exposure to wildfire smoke was associated with significantly elevated risks of several cancers, including lung, colorectal, breast, bladder, and blood cancers, according to evidence from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial presented in a poster and press...
Geriatric Assessment Is the Future: Retiring Karnofsky and ECOG Performance Status in Modern Cancer Care
The purpose of this editorial is to challenge the continued reliance on Karnofsky Performance Status and Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status as primary tools for evaluating older adults with cancer. These measures have been in oncology practice for decades and...
Early Study Finds Intralesional PD-1 Blockade ‘Promising’ for Oral Cancer Prevention
Intralesional nivolumab reduced the size of precancerous lesions and preserved quality of life in patients with oral epithelial dysplasia, according to results from a first-in-human phase I dose-escalation trial presented in a poster and press briefing during the 2026 American Association for...
Tafasitamab/Lenalidomide Combination vs R-CHOP in High-Risk DLBCL: Phase III frontMIND Trial
In patients newly diagnosed with high-risk large B-cell lymphoma, the addition of the CD19 monoclonal antibody tafasitamab plus the immunomodulatory drug lenalidomide (Tafa/Len) to standard therapy led to a 25% reduction in the risk of death or progression in the phase III frontMIND trial....
New Research Links Low Alcohol Consumption to Elevated Health Risks
Researchers reported there was no protective net effect of any level of alcohol consumption on health observed in a new study published by George et al in the Journal of Studies on Alcohol and Drugs. Further, researchers reported that low levels of alcohol use may be associated with elevated health ...
GLP-1 RAs May Reduce Risk of Obesity-Related Cancers
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was associated with a 41% lower risk of developing obesity-associated cancers in the short term for obese, nondiabetic patients, according to findings from an observational study published in Annals of Oncology. “Our study found that...
Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease
Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4...
Music Therapy Noninferior to Cognitive Behavioral Therapy for Anxiety Among Cancer Survivors in Large Telehealth Trial
Guest Editor’s Note: Anxiety is a troubling symptom for many cancer survivors, yet treatment options remain limited. Although cognitive behavioral therapy (CBT) can be beneficial, barriers to access may limit its use. Music therapy, a nonpharmacologic intervention, has been shown to be effective in ...
Which Genes Contribute to Early-Onset Breast Cancer in Black Women?
Black women experience disproportionately elevated risks of developing and dying from early-onset breast cancer. New research published by Beasley et al in Cancer reveals the genes that are most likely to be mutated to contribute to these increased risks. In the study of 686 Black women diagnosed...
AML: All-Oral Regimen Safe and Eases Treatment Administration Burden
An all-oral treatment regimen led to complete responses in almost half of all patients with newly diagnosed acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, according to findings from the phase I/II ASCERTAIN V trial published in The New England Journal of Medicine....
Study Identifies Serious Infection Risks Linked to Antibody-Drug Conjugates
A major real-world study has found serious blood-related side effects associated with antibody-drug conjugates (ADCs), an increasingly important class of targeted cancer therapies. Over the years, many novel ADC therapies have been approved for treating various types of cancers. The study,...
GLP-1 RAs May Be Associated With Lower Breast Cancer Incidence
Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lower the risk of breast cancer incidence, according to findings from a retrospective analysis presented at the 2026 ASCO Annual Meeting (Abstract 10506). The findings were also published in JCO Oncology Practice. “While our...
American Cancer Society Updates Colorectal Cancer Screening Guideline
The American Cancer Society (ACS) recently released updated guidelines for colorectal cancer screening. The new recommendations reaffirm that average-risk adults should begin colorectal cancer screening at age 45 years and continue through age 75 years for those with a life expectancy greater than...
Does Tissue TMB Outperform Blood-Based Testing for Predicting Immunotherapy Response?
A new study from Cleveland Clinic researchers confirms that tissue-derived tumor mutation burden (TMB) remains the more reliable predictor of immunotherapy response in patients with solid tumors. Results were presented at the 2026 ASCO Annual Meeting (Abstract 2580). “This is really a cautionary...
Online Patient Resources About AI and Cancer Found Lacking
Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented at the 2026 ASCO Annual Meeting (Abstract 9000). The study highlighted that the existing webpages...
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in ER-Positive/HER2-Negative Early Breast Cancer
Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, according to findings from a randomized, noninferiority phase III trial presented at the 2026 ASCO...
Friends of Cancer Research Names Richard Pazdur, MD, to Board of Directors
Friends of Cancer Research announced the election of Richard Pazdur, MD, to its Board of Directors. Dr. Pazdur spent 26 years at the U.S. Food and Drug Administration, where he served as the founding director of the Oncology Center of Excellence and played a leading role in shaping the regulatory...
Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease
A comprehensive Cochrane review presented at the 2026 ASCO Annual Meeting suggests that commonly used breast cancer risk prediction models provide only modest accuracy in identifying which women with a family history of breast cancer will ultimately develop the disease (Abstract 10545). Although...
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer
Longer follow-up from the phase III NRG-GY018 trial continues to support the addition of pembrolizumab to standard carboplatin/paclitaxel chemotherapy for patients with primary advanced-stage or recurrent endometrial cancer, according to findings presented during the Gynecologic Oncology Session at ...
Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial
Results from the first randomized controlled trial evaluating a multicancer early detection (MCED) blood test suggest that annual screening with the Galleri test may alter the stage at which cancers are diagnosed, reducing the burden of stage IV cancers. However, the study did not achieve its...
HCC: TACE Plus STRIDE With or Without Lenvatinib
Results from the phase III EMERALD-3 study found that combining the standard treatment of transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab, regular interval durvalumab) regimen, with or without the targeted therapy lenvatinib, can slow the cancer’s...
Symptom-Monitoring App Helps Patients With Advanced Cancer Maintain Quality of Life
Use of a mobile app for proactive symptom monitoring helped patients with advanced cancer who were no longer receiving active anticancer treatment maintain their quality of life and reduced hospital utilization, according to findings from a randomized controlled trial presented at the 2026 ASCO...
Combining Targeted Immunotherapies With Standard R-CHOP Delays Progression of Aggressive B-Cell Lymphomas
Results from the phase III frontMIND trial show that adding tafasitamab and lenalidomide to R-CHOP (rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) for first-line treatment can reduce tumor progression in patients with aggressive diffuse large B-cell lymphoma...
Adjuvant Selpercatinib Deemed ‘Immediately Practice-Changing’ in Early-Stage RET Fusion–Positive NSCLC
The phase III LIBRETTO-432 trial of adjuvant therapy with the central nervous system (CNS)–penetrant oral RET inhibitor selpercatinib met its primary endpoint of improved event-free survival in patients with early-stage RET fusion–positive non–small cell lung cancer (NSCLC), based on data presented ...
Daraxonrasib Extends Median Survival in Previously Treated Pancreatic Cancer
Median Overall survival was nearly doubled among patients with previously treated metastatic pancreatic cancer who received the multiselective RAS(ON) inhibitor daraxonrasib in the phase III RASolute 302 trial, the results of which were presented at the Plenary Session of the 2026 ASCO Annual...
PROTEUS: Perioperative Apalutamide Plus ADT May Set New Standard in High-Risk Localized Prostate Cancer
For decades, perioperative systemic therapy has failed to improve long-term outcomes after radical prostatectomy in high-risk localized prostate cancer. The phase III PROTEUS trial may be the first to break that pattern. Presented as LBA1 during the Plenary Session at the 2026 ASCO Annual Meeting,...
ASCO Collaborates With Ryght AI to Accelerate Site Selection for Metastatic Breast Cancer Trial
ASCO has announced a collaboration with Ryght AI aimed at accelerating the identification and activation of research sites for the CDK4/6 Inhibitor Dosing Knowledge (CDK) Study, a clinical trial evaluating different starting doses of CDK4/6 inhibitors in patients with metastatic breast cancer. The...
First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
The EGFR-targeting tyrosine kinase inhibitor sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) driven by EGFR exon 20 insertion mutations (EGFR exon20ins). Results from the phase III...
